Roxane Can Fix Arguments In Jazz's Xyrem Patent Suit
A New Jersey federal judge denied Jazz Pharmaceuticals Inc.'s appeal of an order allowing Roxane Laboratories Inc. to amend its invalidity and noninfringement arguments in a suit over a planned generic...To view the full article, register now.
Already a subscriber? Click here to view full article